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Abstract
Background: Airway Bypass is a catheter-based, bronchoscopic procedure in which new passageways are created
that bypass the collapsed airways, enabling trapped air to exit the lungs. The Exhale Airway Stents for Emphysema
(EASE) Trial was designed to investigate whether Exhale
® Drug-Eluting Stents, placed in new passageways in the
lungs, can improve pulmonary function and reduce breathlessness in severely hyperinflated, homogeneous
emphysema patients (NCT00391612).
Methods/Design: The multi-center, randomized, double-blind, sham-controlled trial design was posted on http://
www.clinicaltrials.gov in October 2006. Because Bayesian statistics are used for the analysis, the proposed
enrollment ranged from 225 up to 450 subjects at up to 45 institutions. Inclusion criteria are: high resolution CT
scan with evidence of homogeneous emphysema, post-bronchodilator pulmonary function tests showing: a ratio
of FEV1/FVC < 70%, FEV1≤50% of predicted or FEV1 < 1 liter, RV/TLC≥0.65 at screening, marked dyspnea score ≥2
on the modified Medical Research Council scale of 0-4, a smoking history of at least 20 pack years and stopped
smoking for at least 8 weeks prior to enrollment. Following 16 to 20 supervised pulmonary rehabilitation sessions,
subjects were randomized 2:1 to receive either a treatment (Exhale
® Drug-Eluting Stent) or a sham bronchoscopy.
A responder analysis will evaluate the co-primary endpoints of an FVC improvement ≥12% of the patient baseline
value and modified Medical Research Council dyspnea scale improvement (reduction) ≥1 point at the 6-month
follow-up visit.
Discussion: If through the EASE Trial, Airway Bypass is shown to improve pulmonary function and reduce dyspnea
while demonstrating an acceptable safety profile, then homogeneous patients will have a minimally invasive
treatment option with meaningful clinical benefit.
Trial Registration: ClinicalTrials.gov: NCT00391612
Background
The primary objective of the EASE randomized, double-
blind study is to evaluate the safety and effectiveness of
the Exhale
® Drug-Eluting Stent (Broncus Technologies,
Mountain View, CA) in homogeneous emphysema sub-
jects with severe hyperinflation.
According to the National Center for Health Statistics,
over 3.7 million adults in the United States report being
diagnosed with emphysema, a chronic, progressive, irre-
versible disease of the lungs (1). It is an under-diagnosed
and incurable disease often associated with chronic
bronchitis and conditions such as pulmonary hyperten-
sion and heart failure. Emphysema patients suffer from
hyperinflation because of the decrease in the elastic
recoil of the lungs which, along with airway collapse,
increases expiratory flow resistance. This is reflected in
an increase in residual volume (RV), a reduction in
expiratory flows (as measured by forced vital capacity
[FVC] and forced expiratory volume in 1 second [FEV1])
and an increase in dyspnea. In end-stage emphysema,
even a mild exacerbation can cause the patient’sc o n d i -
tion to deteriorate rapidly with profound hypoxemia,
hypercapnia, and respiratory acidosis.
* Correspondence: pallav.shah@ic.ac.uk
1Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK, and Imperial
College London, UK
Full list of author information is available at the end of the article
Shah et al. BMC Pulmonary Medicine 2011, 11:1
http://www.biomedcentral.com/1471-2466/11/1
© 2011 Shah et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.There is currently no cure for emphysema and the
goal of treatment is primarily to relieve symptoms and
reduce exacerbations. For patients with a heterogeneous
pattern of emphysema and upper lobe predominance,
lung volume reduction surgery can offer significant ben-
efit but with morbidity and mortality. Lung transplanta-
tion is a widely-accepted surgical treatment for
homogeneous (diffuse) emphysema. It is, however, an
unrealistic option for most patients as lung transplant
eligibility is limited both by stringent patient selection
criteria and the scarcity of donor lungs. In the US in
2009, approximately 434 lung transplants were per-
formed because of emphysema/COPD (2). A minimally
invasive treatment that improves pulmonary function
and reduces dyspnea in patients with homogeneous
emphysema would provide a significant new option for
these patients. Airway Bypass is a bronchoscopic proce-
dure currently under evaluation to determine if creating
small extra-anatomic openings between the diseased
lung and the distal bronchi can reduce hyperinflation in
homogeneous emphysema patients.
The EASE Trial is a multi-center, randomized, double-
blind, sham-controlled study design. The endpoints for
safety and effectiveness are measured at 6 months after
the procedure.
Methods/Design
The ethics committee of the participating centers
approved the trial and all subjects signed an informed
consent prior to entering the study. A minimum of 225
and a maximum of 450 subjects can be randomized
under this Bayesian study design. All participants receive
standard medical management for the duration of the
study. Each subject who meets all eligibility criteria is
randomized to one of the two groups, receiving the
Exhale Drug-Eluting Stents or sham bronchoscopy,
assigned 2:1 using a computer program.
The Exhale Drug-Eluting Stent (DES) is used in the
Airway Bypass procedure with the Exhale Doppler Sys-
tem, the Exhale
® Transbronchial Dilation Needle and
commercially available inflation syringes and bronchus-
blocking balloons. All of the catheters fit in a broncho-
scope working channel of 2 mm or larger. The Exhale
®
Doppler Probe (Figure 1), when connected to the Dop-
pler Processing Unit (DPU) enables the physician to
eliminate potential Airway Bypass sites which are asso-
ciated with an adjacent blood vessel. The long flexible
Doppler catheter is inserted through the working chan-
nel of a bronchoscope and has a 1.4 mm diameter, 8
MHz ultrasound transducer at the distal tip. At its prox-
imal end a connector plugs into the DPU.
The transbronchial dilation needle (Figure 2) pierces
the airway wall and dilates the passage, allowing place-
ment of the Exhale DES. The device is comprised of a
dilation balloon and a 25 gauge needle that extends up
to 4 mm beyond the distal end of the balloon. Following
passage creation, the area around the passage is
rescanned by using the Doppler probe to further reduce
the risk of encountering a blood vessel during stent
placement.
An Exhale DES supports the newly-created passage
connecting the lung tissue to the natural airway. The
Exhale DES is pre-loaded on a balloon delivery catheter
(Figure 3) which expands to place the stent (Figure 4) in
the new passage. The Exhale Drug-Eluting Stent
(3.3 mm inner diameter channel, 5.3 mm outer diameter
with the stent deployed, with a flare at each end, 2 mm
in length) is composed of stainless steel and silicone
that contains the drug paclitaxel, which is intended to
inhibit fibrotic or other tissue growth in the passage.
The drug elutes into the airway wall and lung tissue
over time, with most of the drug released during the
first month following the procedure.
T h eA i r w a yB y p a s sp r o c e d u r e( F i g u r e5 )i n v o l v e s4
different steps: 1) A Doppler probe scans the selected
a i r w a ya r e ai no r d e rt of i n dt h eq u i e ts p o ti nw h i c h
there are no identifiable sounds of blood flowing and
thus no major blood vessels; 2) The airway wall is then
Figure 1 Exhale Doppler probe tip.
Figure 2 Exhale Transbronchial Dilation Needle (extended tip),
with the dilation balloon inflated.
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retracted, the catheter is advanced and the dilating bal-
loon is inflated to widen the passage; 3) The passage
and adjacent area are rescanned with the Doppler probe
to confirm the absence of surrounding blood vessels; 4)
The needle is withdrawn and the catheter containing
the drug-eluting stent is positioned within the passage-
way and the stent deployed by an inflating balloon.
Inclusion/Exclusion Criteria
Table 1 summarizes the inclusion criteria which are
similar to most of the criteria used in the National
Emphysema Treatment Trial (NETT) (3).
Exclusion criteria (Table 2) are also similar to those
used in NETT. The potential for electrical interference
f r o mt h eE x h a l eD P Ud u r i n gA i r w a yB y p a s sp o s e sa
potential limitation for subjects with implanted defibril-
lators or pacemakers and therefore, these subjects can-
not participate in the study.
Pulmonary function tests listed in the inclusion/exclu-
sion criteria are performed according to standards that
have been jointly developed by the American Thoracic
Society/European Respiratory Society (ATS/ERS), and
the National Emphysema Treatment Trial Manual of
Operations.
Radiology assessment
Both thick and thin slice CT scans were obtained at full
inspiration (total lung capacity) and at the end of
expiration (residual volume). The scanners were evalu-
ated for each of the centres by performing a CT scan on
a phantom. The approval process and radiological
assessment was performed by the core lab (MedQIA,
Los Angeles, CA, USA) using a novel standardized com-
puter assisted diagnosis technique with quantitative
image analysis). The radiology core lab quantified the
percent of emphysema in a lobe using the objective
Density Mask method in which the percent of emphy-
sema is defined as the percentage of voxels with
attenuation values below a specified level in a given
lobe. Attenuation values of ≤-910 Hounsfield units (HU)
from a thick section (10 mm) scan are considered
emphysematous. The severity and distribution of
emphysema are determined from high-resolution com-
puter tomography (CT) scans in a manner similar to the
definition used in NETT: Each lobe of the lung, except
the middle lobe, is assessed and assigned a grade of 0, 1,
2, 3 or 4 based on the percent of lung destruction
within the lobe (as shown in Table 3). Homogeneous
emphysema is defined as a difference in scores of less
than two between the two lobes in at least one lung,
with an overall score of ≥8. (Note that using the NETT
criteria, if one lung was scored to have heterogeneous
emphysema, then that subject was categorized as
heterogeneous.)
Medical treatment and pulmonary rehabilitation
Throughout the duration of the trial, the standard medi-
cal care management program all subjects receive is
consistent with the recommendations of the American
Thoracic Society/European Respiratory Society ATS/
ERS Standards for the Diagnosis and Management of
Patients with COPD (updated 2005). Prior to baseline
testing, the pulmonary rehabilitation program consists
of completion of 16-20 supervised exercise sessions over
6 to 10 weeks, ideally attending 2-3 pulmonary rehabili-
tation sessions per week. Completion of maintenance
pulmonary rehabilitation or 16-20 sessions is an inclu-
sion criterion for the trial. Post-operatively, 10 super-
vised exercise sessions over 8-9 weeks is required.
Bronchoscopy
The blinding of investigators requires two trial teams:
One performing the Airway Bypass and sham broncho-
scopy procedures (Bronchoscopy Team), whereas a
separate blinded team (Assessment Team) conducts the
Figure 3 Exhale Drug-Eluting Stent (white), and underlying
balloon mounted on the delivery catheter. The rounded tip at
the end of the catheter makes it easier to place the stent catheter
in the passage.
Figure 4 Exhale Drug-Eluting Stents.
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preserve the blinding, review and discussion of all post-
procedure chest x-rays and CTs are conducted in the
absence of Assessment Team members. Bronchoscopy is
performed under general anesthesia or deep sedation
with amnesic properties. Investigators use the same
sedation or anesthetic protocols for treated and control
subjects alike. The control group subjects are sedated
and undergo bronchoscopy as if they were receiving Air-
way Bypass, but no passages are created or stents
placed. Bronchial washings for culture are obtained first,
followed by Doppler scanning in the right middle lobe.
The bronchoscope is then retracted to a point below the
vocal cords and above the carina. Simulated stent inser-
tion is performed in this region and the duration of the
sham procedure is at least one hour.
In the treatment group, up to 6 Exhale DES (optimally
a minimum of 1 per treated lobe, maximum 2 per trea-
ted lobe, 6 overall) are placed. The right middle lobe
and any lobe that has a CT score of zero are not trea-
ted. The number and location of the placed stents is
determined by the investigator’s visual assessment of the
anatomic features of the airways and the amount and
type of tissue destruction. Stent placements are targeted
to segmental airways leading to regions where tissue
destruction and air trapping are noted in the inspiratory
and expiratory CT scans. In addition to this subjective
assessment, for each case (treatment or sham) the
bronchoscopist is provided with a radiologist report that
includes lobular volume data and an analysis of specific
segmental airways in the lung lobes (3 segments in the
right upper lobe, left upper lobe and left lower lobe and
5 segments in the right lower lobe) from the core lab.
Figure 5 Airway Bypass procedure steps.
Table 1 EASE Trial Inclusion Criteria
History and physical Age ≥35 years
Subject agrees to consult with a cardiologist prior to randomization if findings determine the need for such a consultation
HRCT scan Patient diagnosed by radiology core lab with evidence of homogeneous emphysema with a total score of ≥8
Pulmonary Function Post-bronchodilator ratio of FEV1/FVC <70%
Post-bronchodilator FEV1 ≤50% of predicted or FEV1 < 1 liter
Post-bronchodilator RV >180% of predicted
Post-bronchodilator RV/TLC ≥0.65 at screening
Dyspnea Marked dyspnea, scoring ≥2 on the modified Medical Research Council scale of 0-4, confirmed at the end of pulmonary
rehabilitation
Arterial blood gas
analysis
PaO2 ≥45 mmHg on room air
Rehabilitation Supervised pulmonary rehabilitation of 16-20 sessions over 6-10 weeks prior to the scheduled study procedure
Smoking A smoking history of at least 20 pack-years (1 pack year = 1 pack/day for 1 year) and subject has stopped smoking at least 8
weeks prior to signing the informed consent
Consent Subject has provided written informed consent using a form that has been reviewed and approved by the Institutional
Review Board or Ethics Committee
Follow-up Subject is willing to be maintained on standard medical therapy for emphysema for 12 months following the procedure
Subject is willing and able to return for all required follow-up and supervised pulmonary rehabilitation visits following study
enrollment
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millimeters of the proximity to tissue destruction, airway
diameter, and average airway wall thickness. The pre-
sence of blood vessels is also noted. It is expected that
regardless of plan for stent placement, the presence of
blood vessels or an inability to place a stent could result
in a stent located in a nearby but perhaps less desirable
airway.
Post-procedure
Subjects are expected to remain in the hospital and mon-
itored for at least 1 night following their intervention.
Prior to being discharged, and at follow-up visits at
months 1, 3, 6, and 12, all subjects are asked to complete
a “Study Subject Questionnaire” to assess the success of
the blind before any testing is performed at each visit.
Following the procedure, study subjects undergo another
8-9 weeks of supervised pulmonary rehabilitation.
Subjects in both control and treatment arms undergo
evaluations at months 1, 3, 6, and 12 (Table 4). After all
tests are completed (at the 12-month visit), subjects are
told if they are in the treatment or the control group.
Treated subjects are asked to return once a year for 4
more years for examinations and testing. The study is
subject to intent-to-treat analysis and all reasonable
efforts are made to contact terminated subjects for fol-
low-up data collection for the first 12 months.
An independent Data Safety and Monitoring Board
evaluates the progress of the study and assesses all
adverse events. The safety stopping rules are described
in Table 5.
T h ep r i m a r ys a f e t ye n d p o i n ti sac o m p a r i s o no fa
composite of five severe adverse events (SAEs) endpoint
between the treatment and control groups. Composite
safety is computed for each subject at each follow-up
visit. The composite score recognizes a subject as having
a safety concern if one or more of the five SAEs in
Table 6 have been reported during the scheduled dura-
tion of the study.
Statistical Analysis
A Bayesian adaptive approach to the sample size selection
is used with various operating characteristics and simula-
tions performed to evaluate statistical power. A minimum
total sample size of 225 and a maximum of 450 are con-
sidered. An interim data look is made when 225 subjects
Table 2 EASE Trial Exclusion Criteria
Pulmonary Function Change in FEV1 > 20% between pre-and post-bronchodilator measurements or >200 mL if the subject’s post-bronchodilator
FEV1 < 1 liter
Clinically significant bronchiectasis
Three or more respiratory infections requiring hospitalization in the last 12 months
Respiratory infection <30 days prior to randomization
Presence of segmental atelectasis, lobar consolidation, significant or unstable pulmonary infiltrate or pneumothorax
confirmed on x-ray
DLco <15% of predicted
Arterial blood gas
analysis
Values on room air, pH <7.35 with a PaCO2 > 50 mmHg or PaCO2 > 60 mmHg regardless of pH
Physical BMI >31.1 for males and >32.3 for females
Unplanned weight loss >10% usual weight in 90 days prior to randomization
General Medical Uncontrolled hypertension (systolic >200 mmHg or diastolic >110 mmHg)
Stroke within last 12 months
Suspicion or history of pulmonary hypertension, defined by either of the following: Abnormal Radionuclide Ventriculogram/
Echocardiogram showing Right Ventricular Ejection Fraction <30%; or evidence of right ventricular dilatation; or evidence of
hypokinesia; or RVSP >45 mmHg
Myocardial infarction within 6 months
Type 1 diabetes
Current diagnosis of renal failure
Lung cancer or pulmonary nodule requiring surgery
Ventilator dependence
Previous lung volume reduction surgery or lobectomy
Known hypersensitivity to aspirin, paclitaxel or stainless steel
Table 3 Emphysema Lobar Grading
Lung Grade Percentage of Lung Destruction within the Lobe
0 No lung destruction
1 1-25% lung destruction
2 26-50% lung destruction
3 51-75% lung destruction
4 76-100% lung destruction
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will be stopped. If accrual continues, another look is made
after 45 additional subjects have been accrued. These 45
subject increment looks continue until accrual is stopped
or 450 subjects are accrued.
To determine effectiveness, the treatment arm (Airway
Bypass) is compared to the control arm (sham broncho-
scopy). The two primary efficacy outcomes, FVC and
mMRC, are combined in a responder analysis. A subject
is a success (responder) if their FVC improves by at
Table 4 Survey, Examination Schedule and Clinical Parameters
Procedure Initial
Screening
Baseline
Testing
Procedure
Day
Post-
Procedure
Days 1-2
Month
1±7
days
Month
3±1 4
days
Month
6±1 4
days
Month
12 ±
14
days
Years 2-5 ± 60
days (treated
subjects)
Health Inventory X X X X X X X
HRCT Scan performed in certified
scanner
X
1 X
5 XX
7
Chest X-Ray X
2 X
5
Pulmonary Rehabilitation - Supervised 16-20 sessions over 6-
10 weeks
After discharge for 8-9 weeks
Cotinine, carboxyhemoglobin, or carbon
monoxide
X
2 X
3 X
Photograph X
2 XX
Blinding assessment questionnaire X X X X X
St. George’s Respiratory Questionnaire X
3 XXXXX
Quality of Well-being scale X
3 XXXXX
Medical History (or interval history) X
2 XXXXX
ASAPSC (Anesthesia score) X
Dyspnea Index (modified mMRC) X
2 X
3 X XXXXX
Physical Exam, to include RR, HR, SpO2 X
3 XXXXX
Electrocardiogram X
3
Spirometry X
2 X
3 X XXXXX
Body Plethysmography X
2 X
3 X XXXXX
DLco X
2 X
3 XXXX
Echocardiography to rule out
pulmonary hypertension and congestive
heart failure
X
2
Pregnancy test (women of child-bearing
age)
X
4
CBC, Blood Chemistry Panel X
3 XXXX
PTT/INR/PT (only if on acticoagulation
therapy)
X
3
Serum Creatinine X
3
Arterial Blood Gases X
2 X
3 X
6-Minute Walk (with BORG scores) X
3 XXXX
Cycle Ergometry (work output) X
3 X
Intraveneous antibiotic X
Begin aspirin X (post op)
Begin oral antibiotic and give subject
pocket ID card
X
1 Within 6 months prior to randomization
5 As soon as possible following treatment, and interpreted by the
Bronchoscopy investigator (not the Assessment investigator)
2 Within 4 months prior to randomization
3 Within 4 weeks prior to randomization and following at least 6 weeks of
supervised pulmonary rehabilitation
6 Required pre- and post-op.
4 Within 24-hours prior to intervention day
7 CT scan at 12 months for Airway Bypass subjects only
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improves (is reduced) by at least 1 point at their 6-
month follow-up visit. In order for superior efficacy to
be claimed, the probability of a subject being a respon-
der in the treatment arm must be greater than the con-
trol arm. The primary efficacy analysis will be on an
intent-to-treat basis on all subjects who enter the proce-
dure room for intervention.
Secondary endpoints will be analyzed using 6 month
data. A responder analysis will be done separately for
mMRC and for FVC. Only those subjects with complete
6-month data will be included in this analysis. Sensitivity
analyses will be done to investigate the possible effects
of missing data. The secondary endpoint Residual
Volume/Total Lung Capacity (RV/TLC) will be analyzed
for superiority. Other secondary endpoints analyzed are:
R V ,F V C ,m M R C ,F E V 1,S t .G e o r g e ’s Respiratory Ques-
tionnaire, 6-minute walk test, and cycle ergometry.
For subjects who are excluded between randomization
and procedure the following information will be col-
lected and reported to the US Food and Drug Adminis-
tration: reason for dropout, randomization assignment,
and baseline data. The patients and A team investigators
are un-blinded at 12 months (Figure 6).
Discussion
A preliminary clinical evaluation of the Exhale DES in a
previous open-label protocol has demonstrated 6 month
improvement in pulmonary function and subjective
improvement in some subjects (4). This largest clinical
study of Airway Bypass published that thirty-five emphy-
sema subjects had an average of 8 Exhale DES implanted.
Six months after the procedure, the mean decrease for all
subjects was a statistically significant 400 mL in RV from
baseline (p = 0.04) and 0.5 points (p = 0.025) in mMRC
dyspnea score. The median RV/TLC ratio for the subjects
at baseline was 0.67. For the most hyperinflated subjects
(defined as those above this median) the decrease in RV
at 6 months was 870 mL (p = 0.022) and mMRC also
decreased by 0.5 points (p = 0.035). While the 17.8%
improvement in FVC over baseline for this group was
not statistically significant, it was higher than the 12%
generally recognized as clinically significant (5).
A variety of factors may influence the study outcome.
Correct technical placement of stents is important and in
itself is influenced by a number of factors such as broncho-
scopic accessibility and vascularity of the target sites. The
duration of benefit of a successfully-placed stent also
remains unclear. Finally, the effect of the 2 to 1 randomiza-
tion (treatment to sham) may also influence the results.
Where randomization to treatment is greater than a 1 to 1
ratio there may be a greater placebo effect, as most patients
b e l i e v et h e yh a v eb e e nr a n d o m i zed to treatment. This is the
first randomized trial of endoscopic treatment designed spe-
cifically for patients with homogenous emphysema. Since
patterns of response in such patients have not been yet stu-
died, we anticipate that this trial will bring to light new
aspects and add to the current knowledge yielding to further
investigation of endoscopic procedures for emphysema.
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Table 5 Safety Stopping Rules
Adverse
Event
Stopping Rule
Major
hemoptysis
> 3 of first 100 subjects then
> 3% subjects or
> 2 subjects/study site
Respiratory
failure
> 15 of first 100 subjects then
> 15% subjects or
> 2 subjects/study site
Pneumothorax > 4 of first 20 subjects then
> 20% subjects or
> 2 subjects/study site
Death ≥2 of first 66 subjects within 30 days post procedure or
>3% thereafter
Table 6 Safety Outcomes
1 Major hemoptysis: ≥200 mL estimated blood loss or requiring
transfusion, or requiring arterial embolization, or surgical/endoscopic
intervention
2 Respiratory failure requiring mechanical ventilation ≥24 hours
3 Pulmonary infection or COPD exacerbation requiring hospitalization
>7 days
4 Pneumothorax requiring tube drainage >7 days
5 Death within 30 days of device implantation or the initial
hospitalization if longer than 30 days, and death from respiratory
causes
Informed Consent
Screening
Meet Inclusion Criteria Do not meet all inclusion criteria
One or more exclusion criteria
Randomised
Procedure: Treatment Procedure; Sham
6 Months 
Endpoint 
Assessments
12 Months
Un-blinding
Figure 6 CONSORT flowchart.
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